{"id":101893,"date":"2025-05-14T22:17:15","date_gmt":"2025-05-14T22:17:15","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/101893\/"},"modified":"2025-05-14T22:17:15","modified_gmt":"2025-05-14T22:17:15","slug":"human-genetics-market-set-to-surge-to-71-1-billion-by-2033-at","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/101893\/","title":{"rendered":"Human Genetics Market Set to Surge to $71.1 Billion by 2033 at"},"content":{"rendered":"<p>        <a href=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/05\/L514318814_g.jpg\" data-fancybox=\"prid-4016198\" title=\"Human Genetics Market\" data-caption=\"Human Genetics Market\" rel=\"nofollow\"><img decoding=\"async\" class=\"pm-img-xl\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/05\/L514318814_g.jpg\" alt=\"Human Genetics Market\"\/><\/a><\/p>\n<p class=\"pm-img-details\">Human Genetics Market<\/p>\n<p>As of 2023, the global Human Genetics Market was valued at $27.0 billion. Projections indicate that this market is poised to reach $71.1 billion by 2033, growing at a CAGR of 10.8% from 2024 to 2033. The global Human Genetics Market has witnessed substantial growth over the past decade, driven by advancements in genetic research, a rising prevalence of genetic disorders, and an increasing demand for personalized medicine. This report provides an in-depth analysis of the market&#8217;s current statistics, growth factors, segmentation, and key players, offering a comprehensive overview of this dynamic industry.<\/p>\n<p>Get Sample PDF Copy Here: https:\/\/www.alliedmarketresearch.com\/request-sample\/A324831 <\/p>\n<p>Human Genetics Market Growth Factors<br \/>&#13;<br \/>\nSeveral pivotal factors contribute to the robust expansion of the Human Genetics Market:<br \/>&#13;<br \/>\n    1. Advancements in Genetic Research: Continuous innovations in genetic testing and sequencing technologies have revolutionized the field, enabling more accurate and efficient analysis of genetic information.<br \/>&#13;<br \/>\n    2. Increasing Prevalence of Genetic Disorders: The rising incidence of genetic conditions, such as Down syndrome, neural tube defects, and congenital heart defects, has heightened the demand for genetic testing and counseling services. <br \/>&#13;<br \/>\n    3. Growing Demand for Personalized Medicine: The shift towards tailored medical treatments based on individual genetic profiles has propelled the adoption of genetic services in clinical practice.<br \/>&#13;<br \/>\n    4. Integration of Genomics in Clinical Practice: The incorporation of genomic data into routine healthcare has enhanced disease diagnosis, prognosis, and treatment strategies, further driving market growth.<br \/>&#13;<br \/>\n    5. Technological Innovations: The development of advanced tools and platforms for genetic analysis has streamlined workflows and reduced costs, making genetic services more accessible.<\/p>\n<p>Human Genetics Market Segmentation<br \/>&#13;<br \/>\nThe Human Genetics Market can be segmented based on test type and application:<br \/>&#13;<br \/>\n    1. By Test Type:<br \/>&#13;<br \/>\n        \u25e6 Non-Invasive Prenatal Testing (NIPT): Screening tests that analyze fetal DNA in maternal blood to detect chromosomal abnormalities.<br \/>&#13;<br \/>\n        \u25e6 Carrier Testing: Identifies individuals who carry a gene for certain inherited conditions.<br \/>&#13;<br \/>\n        \u25e6 Pharmacogenomic Testing: Assesses how genes affect an individual&#8217;s response to medications.<br \/>&#13;<br \/>\n        \u25e6 Karyotype Testing: Examines chromosomes to detect genetic abnormalities.<br \/>&#13;<br \/>\n        \u25e6 Thrombophilia Testing: Detects genetic mutations associated with blood clotting disorders.<br \/>&#13;<br \/>\n        \u25e6 Septin 9 Biomarker Testing: Used for colorectal cancer screening by detecting methylated Septin 9 DNA in blood.<br \/>&#13;<br \/>\n        \u25e6 Next-Generation Sequencing (NGS): High-throughput sequencing methods that allow rapid sequencing of entire genomes or targeted regions.<br \/>&#13;<br \/>\n        \u25e6 Others: Includes various emerging genetic tests catering to specific conditions.<br \/>&#13;<br \/>\n    2. By Application:<br \/>&#13;<br \/>\n        \u25e6 Oncology: Genetic tests used for cancer risk assessment, diagnosis, and treatment planning.<br \/>&#13;<br \/>\n        \u25e6 Cardiology: Genetic analysis for identifying hereditary heart conditions and guiding treatment.<br \/>&#13;<br \/>\n        \u25e6 Neurology: Genetic testing for neurological disorders such as Alzheimer&#8217;s and Parkinson&#8217;s disease.<br \/>&#13;<br \/>\n        \u25e6 Rare Diseases: Identification and diagnosis of uncommon genetic disorders.<br \/>&#13;<br \/>\n        \u25e6 Reproductive Health: Genetic services related to fertility, prenatal screening, and newborn testing.<br \/>&#13;<br \/>\n        \u25e6 Others: Applications in various other medical fields where genetics play a role.<\/p>\n<p>Have Any Query? Ask Our Experts: https:\/\/www.alliedmarketresearch.com\/purchase-enquiry\/A324831 <\/p>\n<p>Key Players in the Human Genetics Market<br \/>&#13;<br \/>\nThe Human Genetics Market features several prominent companies that have significantly contributed to its development:<br \/>&#13;<br \/>\n    \u2022 Thermo Fisher Scientific Inc.<br \/>&#13;<br \/>\n    \u2022 Illumina, Inc.<br \/>&#13;<br \/>\n    \u2022 Agilent Technologies, Inc.<br \/>&#13;<br \/>\n    \u2022 Bio-Rad Laboratories, Inc.<br \/>&#13;<br \/>\n    \u2022 F. Hoffmann-La Roche Ltd.<br \/>&#13;<br \/>\n    \u2022 QIAGEN N.V.<br \/>&#13;<br \/>\n    \u2022 PerkinElmer, Inc.<br \/>&#13;<br \/>\n    \u2022 Becton, Dickinson and Company<br \/>&#13;<br \/>\n    \u2022 Myriad Genetics, Inc.<br \/>&#13;<br \/>\n    \u2022 23andMe, Inc.<\/p>\n<p>The Human Genetics Market is on a trajectory of significant growth, fueled by technological advancements, an increasing burden of genetic disorders, and a shift towards personalized healthcare. As the integration of genomics into clinical practice continues to evolve, the market is expected to expand further, offering new opportunities and challenges. Stakeholders, including healthcare providers, researchers, and policymakers, must collaborate to harness the full potential of human genetics, ensuring that these advancements translate into improved health outcomes globally.<\/p>\n<p>Read Full Market Synopsis: https:\/\/www.alliedmarketresearch.com\/human-genetics-market-A324831 <\/p>\n<p>Thanks for reading this article; you can also get an individual chapter-wise sections or region-wise report versions like North America, LATAM, Europe, or Southeast Asia.<\/p>\n<p>Contact Us:<br \/>&#13;<br \/>\nDavid Correa<br \/>&#13;<br \/>\n5933 NE Win Sivers Drive<br \/>&#13;<br \/>\n#205, Portland, OR 97220<br \/>&#13;<br \/>\nUnited States<br \/>&#13;<br \/>\nUSA\/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022<br \/>&#13;<br \/>\nUK: +44-845-528-1300<br \/>&#13;<br \/>\nHong Kong: +852-301-84916<br \/>&#13;<br \/>\nIndia (Pune): +91-20-66346060<br \/>&#13;<br \/>\nFax: +1(855)550-5975<br \/>&#13;<br \/>\nhelp@alliedmarketresearch.com<br \/>&#13;<br \/>\nWeb: https:\/\/www.alliedmarketresearch.com<\/p>\n<p>About Us:<br \/>&#13;<br \/>\nAllied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of &#8220;Market Research Reports&#8221; and &#8220;Business Intelligence Solutions.&#8221; AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.<\/p>\n<p>This release was published on openPR.<br \/>\n        <\/p>\n","protected":false},"excerpt":{"rendered":"Human Genetics Market As of 2023, the global Human Genetics Market was valued at $27.0 billion. Projections indicate&hellip;\n","protected":false},"author":2,"featured_media":101894,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3846],"tags":[3369,267,3368,3364,3362,3367,3371,3370,3372,3361,3365,3363,3366,70,16,15],"class_list":{"0":"post-101893","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-advertising","9":"tag-genetics","10":"tag-marketing","11":"tag-media-release","12":"tag-news-release","13":"tag-pr","14":"tag-pr-marketing","15":"tag-pr-service","16":"tag-pr-strategy","17":"tag-presses-release","18":"tag-pressreleases","19":"tag-public-relations","20":"tag-publicity","21":"tag-science","22":"tag-uk","23":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114508506728622142","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/101893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=101893"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/101893\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/101894"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=101893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=101893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=101893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}